Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Q1 FY2025 Earnings Presentation
20 slides from Aurobindo Pharma's earnings presentation, Aug 10, 2024
Slide 1: Cover letter to stock exchanges: Investor / Analysts Presentation
August 10, 2024 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Phiroz Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (E), 25th floor, Dalal Street, MUMBAI -400 051 MUMBAI -400 001 Company Code No. AUROPHARMA Company
Slide 2: Aurobindo Pharma Limited Earnings Presentation Q1FY25
Aurobindo Pharma Limited Earnings Presentation Q1FY25
Slide 3: Disclaimer
Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma Limited, nor shall it, or any par
Slide 4: Table of Content
Table of Content 04 Q1FY25 Business & Financial Highlights 11 Update on biosimilars 13 Financial Summary 13 16 Filings Snapshot 3
Slide 5: Q1FY25 Business & Financial Highlights
Q1FY25 Business & Financial Highlights 4
Slide 6: Key Financial Highlights of the Quarter
Key Financial Highlights of the Quarter Revenue EBITDA Net Profit Q1FY25 ₹ 7,567 Cr ₹ 1,620 Cr ₹ 919 Cr Q1FY24 ₹ 6,851 Cr ₹ 1,151 Cr ₹ 571 Cr Y-o-Y growth % 10.5% 40.7% 61.1% 5
Slide 7: Quarterly Performance – Q1FY25
Quarterly Performance – Q1FY25 Revenue (Rs Crore) US Revenue excluding Puerto Rico (US$ Mn) 451 7,580 7,567 432 426 409 7,352 382 7,219 359 6,851 6,473 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 EBITDA (Rs Crore) Net Debt to Equity 1,687 1,620 1,601 -0.01 1,4
Slide 8: Consolidated Financial & Business Highlights – Q1FY25
Consolidated Financial & Business Highlights – Q1FY25 Basic & Diluted EPS is Rs 15.69| YoY growth of 61.4% Net Capex of US$ 74 million primarily towards capacity enhancements Total investment for Biosimilar project is ~US$ 365 million* till June 30, 2024 Total R&D spend for the quarter is Rs. 339 Cr
Slide 9: Consolidated Operational Performance
Consolidated Operational Performance Rs Crore Q1FY25 Q1FY24 Y-o-Y (%) Q4FY24 Q-o-Q (%) USA** 3,555 3,137 13.3% 3,588 -0.9% Europe 1,982 1,837 7.9% 1,832 8.2% Growth Markets* 709 475 49.2% 852 -16.7% ARV 229 201 13.9% 238 -4.0% Total Formulations 6,475 5,650 14.6% 6,510 -0.5% Beta-lactam 791 719 9.9%
Slide 10: US Formulations Business Performance Highlights (Excluding Puerto Rico)
US Formulations Business Performance Highlights (Excluding Puerto Rico) Revenue (US$ Mn) Commentary 440 432 430 426 420 410 • US revenue in Q1FY25 increased by 11.6% YoY and decreased 400 390 382 by 1.4% QoQ to USD 426 Mn, accounting for 47.0% of 380 370 consolidated revenue 360 350 • Specialty & In
Slide 11: Revenue Break-up by Business
Revenue Break-up by Business Europe (EUR Mn) Growth Markets (US$ Mn) ARV (US$ Mn) API (Rs Crore) 1,092 221 103 1,033 205 1,019 203 85 29 27 58 24 Q1FY24 Q4FY24 Q1FY25 Q1FY24 Q4FY24 Q1FY25 Q1FY24 Q4FY24 Q1FY25 Q1FY24 Q4FY24 Q1FY25 Growth Markets posted revenues of Europe business posted revenues of A
Slide 12: Update on Biosimilars
Update on Biosimilars 11
Slide 13: Advancing our Oncology and Immunology Biosimilar Programs, Biologics
Advancing our Oncology and Immunology Biosimilar Programs, Biologics • CuraTeQ Biologics is a wholly owned subsidiary of Aurobindo Pharma Ltd • Our business strategy primarily focuses on developing Oncology and Immunology biosimilars • Our broader pipeline of 14 biosimilars positions CuraTeQ uniquel
Slide 14: Financial Summary
Financial Summary 13
Slide 15: Summary Consolidated Profit & Loss Statement
Summary Consolidated Profit & Loss Statement Rs Cr Q1FY25 Q1FY24 YoY Chg. (%) Q4FY24 QoQ Chg. (%) Revenue from Operations 7,567 6,851 10.5% 7,580 -0.2% Gross Profit 4,494 3,696 21.6% 4,519 -0.6% Gross Margin 59.4% 53.9% 544 bps 59.6% -22 bps Overheads -2,875 -2,544 13.0% -2,832 1.5% EBITDA (before F
Slide 16: Debt Profile
Debt Profile Gross Debt (US$ Mn) Debt as on (INR Cr) Mar-21 Mar-22 Mar-23 Mar-24 Jun-24 Closing Rate (INR/USD) 73.110 75.793 82.170 83.405 83.387 674 313 592 752 815 758 833 Fx Loan restated in INR 4,929 2,223 4,638 3,994 5,037 Rupee Loan 44 150 224 2,234 1,912 196 Gross Debt 4,972 2,373 4,862 6,318
Slide 17: Filing Snapshot
Filing Snapshot 16
Slide 18: US ANDA Filings Snapshot as on 30th June 2024
US ANDA Filings Snapshot as on 30th June 2024 ANDA Filings Addressable Market Therapy ANDAs Size (US$ Bn)^ CNS 150 26.2 Aurobindo (Excl. Specialty & 800 668 600 Specialty & Injectables 498 300 700 ARV 29 0.4 600 500 250 500 200 170 Injectables) 400 400 150 46.8 300 300 144 CVS 121 116 54 100 200 200
Slide 19: Global Regulatory Filing Details
Global Regulatory Filing Details As at As at As at As at As at As at As at As at As at Category Geography Approvals Mar 17 Mar 18 Mar 19 Mar 20 Mar 21 Mar 22 Mar 23 Mar 24 Jun 24 US* 429 478 541 586 639 727^ 774^ 830 838 FA: 668, TA:26 Europe** 2,521 2,848 3,003 3,214 3,374 3,580 3,751 3,642 3,785 2
Slide 20: Thank You
Digitally signed by BADDIGAM ADI REDDY Date: 2024.08.10 18:38:09 +05'30' Thank You For more information, contact: ir@aurobindo.com; cc@aurobindo.com Investor Relations | Corporate Communications www.aurobindo.com +91 40 6672 1551 | 6672 5005 19